# Petmed Express Inc: overview PETS · Nasdaq · CIK 1040130 · [Consumer staples](/sectors/consumer-staples.md) · fiscal year ends Mar 31 Pages: [Overview](/companies/pets.md) · [Financials](/companies/pets/financials.md) · [Filings](/companies/pets/filings.md) · [Insiders](/companies/pets/insiders.md) Latest reported revenue: [$41.0m](/filings/0001040130-26-000041.md) for Q1 FY2027, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001040130-26-000041). ## Last eight quarters | Line item | Unit | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [58.0](/filings/0001040130-25-000108.md) | [52.0](/filings/0001040130-26-000007.md) | [50.8 d](/filings/0001040130-26-000019.md) | [51.2](/filings/0001040130-26-000041.md) | [44.4](/filings/0001040130-25-000108.md) | [40.7](/filings/0001040130-26-000007.md) | [42.8 d](/filings/0001040130-26-000019.md) | [41.0](/filings/0001040130-26-000041.md) | | Gross margin | % | [32.3%](/filings/0001040130-25-000108.md) | [31.0%](/filings/0001040130-26-000007.md) | [29.9% d](/filings/0001040130-26-000019.md) | [28.1%](/filings/0001040130-26-000041.md) | [28.0%](/filings/0001040130-25-000108.md) | [23.3%](/filings/0001040130-26-000007.md) | [32.6% d](/filings/0001040130-26-000019.md) | [27.6%](/filings/0001040130-26-000041.md) | | Operating margin | % | [1.0%](/filings/0001040130-25-000108.md) | [(0.9%)](/filings/0001040130-26-000007.md) | [(11.9%) d](/filings/0001040130-26-000019.md) | [(66.7%)](/filings/0001040130-26-000041.md) | [(18.9%)](/filings/0001040130-25-000108.md) | [(25.7%)](/filings/0001040130-26-000007.md) | [(13.3%) d](/filings/0001040130-26-000019.md) | [(15.2%)](/filings/0001040130-26-000041.md) | | Net margin | % | [4.0%](/filings/0001040130-25-000108.md) | [(1.4%)](/filings/0001040130-26-000007.md) | [(22.9%) d](/filings/0001040130-26-000019.md) | [(66.7%)](/filings/0001040130-26-000041.md) | [(19.2%)](/filings/0001040130-25-000108.md) | [(26.0%)](/filings/0001040130-26-000007.md) | [(9.5%) d](/filings/0001040130-26-000019.md) | [(15.0%)](/filings/0001040130-26-000041.md) | | Diluted EPS | $ per share | [0.11](/filings/0001040130-25-000108.md) | [(0.03)](/filings/0001040130-26-000007.md) | not reported | [(1.65)](/filings/0001040130-26-000041.md) | [(0.41)](/filings/0001040130-25-000108.md) | [(0.50)](/filings/0001040130-26-000007.md) | not reported | [(0.28)](/filings/0001040130-26-000041.md) | | Free cash flow | $m | [6.1 d](/filings/0001040130-25-000108.md) | [(1.9) d](/filings/0001040130-26-000007.md) | [4.6 d](/filings/0001040130-26-000019.md) | [(13.6)](/filings/0001040130-26-000041.md) | [(4.8) d](/filings/0001040130-25-000108.md) | [(9.2) d](/filings/0001040130-26-000007.md) | [(5.5) d](/filings/0001040130-26-000019.md) | [(8.3)](/filings/0001040130-26-000041.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-03-31) | FY2023 (2023-03-31) | FY2024 (2024-03-31) | FY2025 (2025-03-31) | FY2026 (2026-03-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [272](/filings/0001040130-24-000046.md) | [248](/filings/0001040130-25-000072.md) | [274](/filings/0001040130-26-000019.md) | [227](/filings/0001040130-26-000019.md) | [179](/filings/0001040130-26-000019.md) | | Gross margin | % | [28.3%](/filings/0001040130-24-000046.md) | [30.9%](/filings/0001040130-25-000072.md) | [30.9%](/filings/0001040130-26-000019.md) | [30.5%](/filings/0001040130-26-000019.md) | [28.1%](/filings/0001040130-26-000019.md) | | Operating margin | % | [8.9%](/filings/0001040130-24-000046.md) | [2.4%](/filings/0001040130-25-000072.md) | [(3.0%)](/filings/0001040130-26-000019.md) | [(0.7%)](/filings/0001040130-26-000019.md) | [(32.8%)](/filings/0001040130-26-000019.md) | | Net margin | % | [6.9%](/filings/0001040130-24-000046.md) | [2.1%](/filings/0001040130-25-000072.md) | [(2.7%)](/filings/0001040130-26-000019.md) | [(2.8%)](/filings/0001040130-26-000019.md) | [(32.0%)](/filings/0001040130-26-000019.md) | | Diluted EPS | $ per share | [0.92](/filings/0001040130-24-000046.md) | [0.25](/filings/0001040130-25-000072.md) | [(0.37)](/filings/0001040130-26-000019.md) | [(0.30)](/filings/0001040130-26-000019.md) | [(2.74)](/filings/0001040130-26-000019.md) | | Free cash flow | $m | [16.7](/filings/0001040130-24-000046.md) | [22.5](/filings/0001040130-25-000072.md) | [(0.2)](/filings/0001040130-26-000019.md) | [(0.4)](/filings/0001040130-26-000019.md) | [(33.0)](/filings/0001040130-26-000019.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/pets/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $2.2m | 1,131,230 | | Reduced −55,139 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.6m | 827,397 | | Reduced −4,034 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.1m | 568,255 | | Added +16,578 | | [FEDERATED HERMES, INC.](/funds/1056288.md) | 2026-06-30 | $407.4k | 212,170 | | Reduced −454,635 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $391.9k | 204,075 | | Reduced −17,447 | | [STEEL PARTNERS HOLDINGS L.P.](/funds/1452857.md) | 2026-06-30 | $371.8k | 193,664 | | Unchanged | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $265.6k | 138,330 | | Reduced −95,346 | | [BRIDGEWAY CAPITAL MANAGEMENT, LLC](/funds/1107261.md) | 2026-06-30 | $232.4k | 121,048 | | Reduced −11,676 | | [Rangeley Capital, LLC](/funds/1517796.md) | 2026-06-30 | $232.3k | 121,000 | | Added +11,792 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $212.1k | 110,481 | | Added +769 | ## Recent filings [All 836 filings](/companies/pets/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-28 | 16:27 ET | [8-K](/filings/0001040130-26-000057.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001040130-26-000057 | | 2026-09-21 | 08:35 ET | [8-K](/filings/0001040130-26-000047.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001040130-26-000047 | | 2026-09-17 | 09:08 ET | [8-K](/filings/0001040130-26-000045.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001040130-26-000045 | | 2026-08-13 | 16:58 ET | [10-Q](/filings/0001040130-26-000041.md) | Quarterly report, period 2026-06-30 | 0001040130-26-000041 | | 2026-08-13 | 16:17 ET | [8-K](/filings/0001040130-26-000040.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001040130-26-000040 | | 2026-08-12 | 16:30 ET | [8-K](/filings/0001040130-26-000036.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001040130-26-000036 | | 2026-07-23 | 09:26 ET | [8-K](/filings/0001040130-26-000029.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001040130-26-000029 | | 2026-06-29 | 07:36 ET | [SCHEDULE 13D/A](/filings/0001213900-26-072848.md) | Ownership report, active investor, amended | 0001213900-26-072848 | | 2026-06-26 | 16:10 ET | [8-K](/filings/0001040130-26-000027.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001040130-26-000027 | | 2026-06-25 | 16:19 ET | [DEF 14A](/filings/0001040130-26-000023.md) | Proxy statement, period 2026-08-11 | 0001040130-26-000023 | ## Latest annual report [Form 10-K for the fiscal year ended Mar 31, 2026](/filings/0001040130-26-000019.md), filed Jun 2, 2026. ## Forecast league Q2 FY2027, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/8ee08daa-3090-4087-947d-9be717c94221) ## About the filer - CIK: 1040130 - Tickers: PETS - Exchange: Nasdaq - SIC code: 5912 Retail-Drug Stores and Proprietary Stores - State of incorporation: FL - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:31 ET. No prices; not investment advice.